

# Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)

Technology appraisal guidance

Published: 13 July 2023

[www.nice.org.uk/guidance/ta910](https://www.nice.org.uk/guidance/ta910)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of semaglutide for managing overweight and obesity in young people aged 12 to 17 years. This is because Novo Nordisk has confirmed that it does not intend to make an evidence submission for the appraisal.

Novo Nordisk considers that, at this time, there is not enough evidence to support economic modelling for this population. In particular, there is not enough evidence for the risk equations that explore the link between weight loss and long-term outcomes in young people aged 12 to 17 years and utility estimates that adequately capture the full impact on their quality of life. Therefore, there is a high degree of uncertainty in the evidence base that would be used to support an economic model that meets the NICE reference case.

## Information

If NHS organisations wish to consider semaglutide for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978 1 4731 5287 8

## Accreditation

